Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Economopoulou, A. Pantazopoulos, A. Spathis, I. Kotsantis, A. Kyriazoglou, G. Kavourakis, R. Zakopoulou, I. Chatzidakis, M. Anastasiou, M. Prevezanou, C. Resteghini, L. Licitra, C. Bergamini, E. Colombo, Francesca Caspani, N. Denaro, S. Vecchio, Pierluigi Bonomo, M. Rocca, F. Bertolini, D. Ferrari, A. Psyrri, P. Bossi (2021)
Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic RegionsCells, 11
R. Salgado, R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Eynden, F. Baehner, F. Penault-Llorca, E. Perez, E. Thompson, W. Symmans, A. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D. Rimm, K. Allison, J. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Annals of oncology : official journal of the European Society for Medical Oncology, 26 2
H. Witte, N. Gebauer, Daniela Lappöhn, V. Umathum, A. Riecke, Annette Arndt, K. Steinestel (2020)
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) InfiltrateCancers, 12
Stijn Keukeleire, T. Vermassen, A. Meulenaere, P. Deron, W. Huvenne, F. Duprez, D. Creytens, J. Dorpe, S. Rottey, L. Ferdinande (2021)
Tumour infiltrating lymphocytes in oropharyngeal carcinoma: prognostic value and evaluation of a standardised method.Pathology
M. Yarchoan, Alexander Hopkins, E. Jaffee (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.The New England journal of medicine, 377 25
Russell (2013)
24Head Neck Oncol, 5
A. Goodman, S. Kato, L. Bazhenova, S. Patel, G. Frampton, V. Miller, P. Stephens, G. Daniels, R. Kurzrock (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersMolecular Cancer Therapeutics, 16
S. Cabezas-Camarero, P. Pérez-Segura (2021)
NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER: RATIONALE, CURRENT EVIDENCE AND FUTURE PERSPECTIVE.Critical reviews in oncology/hematology
C. Rodriguez, Qian Wu, J. Voutsinas, J. Fromm, Xiu-yun Jiang, V. Pillarisetty, Sylvia Lee, R. Santana-Davila, B. Goulart, C. Baik, L. Chow, K. Eaton, R. Martins (2019)
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland CancerClinical Cancer Research, 26
V. Sridharan, D. Margalit, Stephanie Lynch, Mariano Severgnini, Jun Zhou, N. Chau, G. Rabinowits, J. Lorch, P. Hammerman, F. Hodi, Robert Haddad, R. Tishler, J. Schoenfeld (2016)
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancerBritish Journal of Cancer, 115
L. Masterson, James Howard, J. Gonzalez-Cruz, C. Jackson, Catherine Barnett, L. Overton, H. Liu, R. Ladwa, Fiona Simpson, M. McGrath, B. Wallwork, T. Jones, C. Ottensmeier, M. Chua, Chris Perry, R. Khanna, B. Panizza, S. Porceddu, M. Lechner (2020)
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?International Journal of Cancer, 146
C. Badoual, S. Hans, J. Rodríguez, S. Peyrard, C. Klein, N. Agueznay, V. Mosseri, O. Laccourreye, P. Bruneval, W. Fridman, D. Brasnu, E. Tartour (2006)
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck CancersClinical Cancer Research, 12
Yi-Xiang Ma, Qiwei Wang, Qian Dong, Lei Zhan, Jingdong Zhang (2019)
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.American journal of cancer research, 9 8
P. Weller, A. Bankfalvi, X. Gu, N. Dominas, G. Lehnerdt, R. Zeidler, S. Lang, S. Brandau, C. Dumitru (2014)
The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer.European journal of cancer, 50 7
R. Cohen, J. Delord, T. Doi, S. Piha-Paul, Stephen Liu, J. Gilbert, A. Algazi, S. Damian, R. Hong, C. Tourneau, D. Day, A. Varga, E. Élez, J. Wallmark, S. Saraf, Pradeep Thanigaimani, Jonathan Cheng, B. Keam (2018)
Pembrolizumab for the Treatment of Advanced Salivary Gland CarcinomaAmerican Journal of Clinical Oncology, 41
L. Chow, R. Haddad, Shilpa Gupta, A. Mahipal, R. Mehra, M. Tahara, R. Berger, J. Eder, B. Burtness, Se-Hoon Lee, B. Keam, Hyunseok Kang, K. Muro, J. Weiss, R. Geva, Chia‐Chi Lin, H. Chung, Amy Meister, M. Dolled-Filhart, K. Pathiraja, Jonathan Cheng, T. Seiwert (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortJournal of Clinical Oncology, 34
Kyriakos Chatzopoulos, A. Collins, S. Sotiriou, Michael Keeney, D. Visscher, M. Rivera, David Schembri-Wismayer, Jean Lewis, P. Greipp, W. Sukov, A. Chintakuntlawar, K. Price, Joaquín García (2020)
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 ExpressionHead and Neck Pathology, 14
N. Amin, C. Maroun, Margueritta Asmar, Hosam Alkhatib, M. Guller, Matthew Herberg, G. Zhu, T. Seiwert, D. Pardoll, D. Eisele, C. Fakhry, C. Gourin, Rajarsi Mandal (2021)
Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: Systematic reviewHead & Neck, 44
E. Cohen, D. Soulières, C. Tourneau, J. Dinis, L. Licitra, M. Ahn, A. Soria, J. Machiels, N. Mach, R. Mehra, B. Burtness, Pingye Zhang, Jonathan Cheng, R. Swaby, K. Harrington, M. Acosta-Rivera, D. Adkins, M. Aghmesheh, M. Airoldi, E. Aleknavičius, Y. Al-farhat, A. Algazi, S. Almokadem, A. Alyasova, J. Bauman, M. Benasso, A. Berrocal, V. Bray, B. Burtness, F. Caponigro, A. Castro, T. Cescon, Kelvin Chan, A. Chaudhry, B. Chauffert, E. Cohen, T. Csőszi, J. Boer, J. Delord, A. Dietz, J. Dinis, C. Dupuis, L. Digue, J. Erfán, Y. Álvarez, M. Evans, M. Fidler, M. Forster, S. Friesland, A. Ganti, L. Geoffrois, C. Grant, V. Gruenwald, K. Harrington, T. Hoffmann, G. Horvai, A. Inčiūra, R. Jang, P. Jankowska, A. Jimeno, M. Joseph, A. Ramiro, B. Karaszewska, A. Kawecki, U. Keilholz, U. Keller, Sung-Bae Kim, J. Kocsis, N. Kotecki, M. Kozloff, J. Lambea, L. Landherr, Yuri Lantsukhay, S. Lazarev, Lip Lee, Igor Lifirenko, D. Martincic, O. Matorin, M. McGrath, K. Misiukiewicz, J. Morris, F. Mufazalov, J. Niu, D. Srinivasan, P. Segura, D. Rauch, Maria Ribeiro, C. Rodriguez, F. Rolland, A. Russo, Á. Ruzsa, Frederico Sanches, S. Shin, Mikhail Shtiveland, D. Soulières, P. Specenier, É. Szekanecz, J. Szota, C. Herpen, Hector Velez-Cortes, W. Walsh, S. Wilop, R. Winterhalder, M. Wojtukiewicz, D. Wong, D. Zandberg (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 393
F. Concha-Benavente, Raghvendra Srivastava, S. Trivedi, Y. Lei, U. Chandran, R. Seethala, G. Freeman, R. Ferris (2016)
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.Cancer research, 76 5
(2018)
Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study, 41
T. Nakano, Katsumi Takizawa, A. Uezato, K. Taguchi, S. Toh, M. Masuda (2019)
Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.Oral oncology, 90
Bin Xu, A. Jungbluth, D. Frosina, Bayan Alzumaili, Nathaniel Aleynick, E. Slodkowska, K. Higgins, A. Ho, L. Morris, R. Ghossein, N. Katabi (2019)
The immune microenvironment and expression of PD‐L1, PD‐1, PRAME and MHC I in salivary duct carcinomaHistopathology, 75
Takashi Mukaigawa, R. Hayashi, K. Hashimoto, Toru Ugumori, N. Hato, S. Fujii (2016)
Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomasJournal of Surgical Oncology, 114
Robert Ferris, G. Blumenschein, J. Fayette, J. Guigay, A. Colevas, L. Licitra, K. Harrington, S. Kasper, E. Vokes, C. Even, F. Worden, Nabil Saba, L. Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. Geese, J. Kopit, James Shaw, Maura Gillison (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.The New England journal of medicine, 375 19
M. Teng, S. Ngiow, A. Ribas, M. Smyth (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer research, 75 11
G. Hanna, Patrick Lizotte, Megan Cavanaugh, F. Kuo, Priyanka Shivdasani, Alexander Frieden, N. Chau, J. Schoenfeld, J. Lorch, R. Uppaluri, L. Macconaill, R. Haddad (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.JCI insight, 3 4
A. Almangush, Stijn Keukeleire, S. Rottey, L. Ferdinande, T. Vermassen, I. Leivo, A. Mäkitie (2022)
Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?Cancers, 14
F. Succaria, P. Kvistborg, Julie Stein, Elizabeth Engle, T. McMiller, L. Rooper, E. Thompson, Alan Berger, M. Brekel, C. Zuur, J. Haanen, S. Topalian, J. Taube (2020)
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomasCancer Immunology, Immunotherapy, 70
M. Ratcliffe, A. Sharpe, M. Rebelatto, M. Scott, C. Barker, P. Scorer, Jill Walker (2016)
A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)Annals of Oncology, 27
Cecilia Nordfors, Nathalie Grün, Nikolaos Tertipis, Andreas Ährlund-Richter, Linnea Haeggblom, L. Sivars, J. Du, T. Nyberg, L. Marklund, E. Munck-Wikland, A. Näsman, T. Ramqvist, T. Dalianis (2013)
CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.European journal of cancer, 49 11
F. Sato, T. Ono, A. Kawahara, Katsuhisa Matsuo, Reiichiro Kondo, Kiminobu Sato, J. Akiba, Toshihiko Kawaguchi, T. Kakuma, S. Chitose, H. Umeno, H. Yano (2020)
Prognostic Value of Tumor Proportion Score in Salivary Gland CarcinomaThe Laryngoscope, 131
Sophie Outh-Gauer, Aurélien Morini, E. Tartour, C. Lépine, A. Jung, C. Badoual (2020)
The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory TreatmentsHead and Neck Pathology, 14
H. Shibata, Shin Saito, R. Uppaluri (2021)
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant ImmunotherapyFrontiers in Oncology, 11
Chiun Hsu, Se-Hoon Lee, S. Ejadi, C. Even, R. Cohen, C. Tourneau, J. Mehnert, A. Algazi, E. Brummelen, S. Saraf, Pradeep Thanigaimani, Jonathan Cheng, A. Hansen (2017)
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 36
F. Sato, J. Akiba, A. Kawahara, Y. Naito, T. Ono, Y. Takase, K. Murata, H. Abe, Tomohiko Yamaguchi, H. Miyoshi, Yushi Abe, Y. Mihara, Masahiko Tanikawa, Momoko Akashi, H. Kurose, H. Umeno, H. Yano (2018)
The expression of programed death ligand‐1 could be related with unfavorable prognosis in salivary duct carcinomaJournal of Oral Pathology & Medicine, 47
A. Näsman, Mircea Romanitan, Cecilia Nordfors, Nathalie Grün, H. Johansson, L. Hammarstedt, L. Marklund, E. Munck-Wikland, T. Dalianis, T. Ramqvist (2012)
Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar CancerPLoS ONE, 7
Q. Fang, Yao Wu, Wei Du, Xu Zhang, Defeng Chen (2021)
Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland CarcinomaFrontiers in Oncology, 11
E. Ruiter, F. Mulder, B. Koomen, E. Speel, M. Hout, Reinout Roest, E. Bloemena, L. Devriese, S. Willems (2020)
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)Modern Pathology, 34
Borghild Ljøkjel, H. Haave, S. Lybak, O. Vintermyr, L. Helgeland, H. Aarstad (2022)
Tumor Infiltration Levels of CD3, Foxp3 (+) Lymphocytes and CD68 Macrophages at Diagnosis Predict 5-Year Disease-Specific Survival in Patients with Oropharynx Squamous Cell CarcinomaCancers, 14
A. Meulenaere, T. Vermassen, S. Aspeslagh, P. Deron, F. Duprez, D. Laukens, J. Dorpe, L. Ferdinande, S. Rottey (2017)
Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancerOncotarget, 8
J. Rodrigo, Mario Sánchez-Canteli, F. López, G. Wolf, J. Hernandez-Prera, M. Williams, S. Willems, A. Franchi, A. Coca-Pelaz, A. Ferlito (2021)
Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis †Biomedicines, 9
S. Russell, T. Angell, M. Lechner, D. Liebertz, A. Correa, Uk Sinha, Niels Kokot, A. Epstein (2013)
Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma.Head & neck oncology, 5 3
R. Ferrarotto, M. Amit, P. Nagarajan, M. Rubin, Ying Yuan, D. Bell, A. El-Naggar, Jason Johnson, W. Morrison, D. Rosenthal, B. Glisson, F. Johnson, Charles Lu, F. Mott, B. Esmaeli, E. Diaz, P. Gidley, R. Goepfert, C. Lewis, R. Weber, J. Wargo, Sreyashi Basu, F. Duan, S. Yadav, P. Sharma, J. Allison, J. Myers, N. Gross (2021)
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckClinical Cancer Research, 27
Alame (2020)
4383Theranostics, 10
M. Linxweiler, F. Kuo, N. Katabi, Mark Lee, Z. Nadeem, Martin Dalin, Martin Dalin, V. Makarov, D. Chowell, S. Dogan, I. Ganly, A. Hakimi, R. Wong, N. Riaz, A. Ho, T. Chan, L. Morris (2020)
The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by SubtypeClinical Cancer Research, 26
A. Hamza, Dianna Roberts, S. Su, R. Weber, D. Bell, R. Ferrarotto (2019)
PD-L1 expression by immunohistochemistry in salivary duct carcinoma.Annals of diagnostic pathology, 40
K. Oguejiofor, J. Hall, C. Slater, G. Betts, G. Hall, N. Slevin, S. Dovedi, P. Stern, C. West (2015)
Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinomaBritish Journal of Cancer, 113
Huanhuan Wang, Qin Zhao, Yuyu Zhang, Qihe Zhang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, L. Meng, Ying Xin, Xin Jiang (2021)
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human PapillomavirusFrontiers in Immunology, 12
Jie Wang, Junshang Ge, Yian Wang, F. Xiong, Jiayue Guo, Xianjie Jiang, Lishen Zhang, Xiangying Deng, Zhaojian Gong, Shanshan Zhang, Qijia Yan, Yi He, Xiayu Li, Lei Shi, Can Guo, Fuyan Wang, Zheng Li, Ming Zhou, Bo Xiang, Yong Li, Wei Xiong, Zhaoyang Zeng (2022)
EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1Nature Communications, 13
B. Meléndez, C. Campenhout, S. Rorive, M. Remmelink, I. Salmon, N. D’haene (2018)
Methods of measurement for tumor mutational burden in tumor tissue.Translational lung cancer research, 7 6
B. Seliger, C. Massa, Bo Yang, D. Bethmann, M. Kappler, A. Eckert, C. Wickenhauser (2020)
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell CarcinomaInternational Journal of Molecular Sciences, 21
G. Schvartsman, D. Bell, M. Rubin, M. Tetzlaff, E. Hanna, J. Lee, R. Weber, J. Phan, B. Glisson, R. Ferrarotto (2021)
The tumor immune contexture of salivary duct carcinomaHead & Neck, 43
S. Klempner, D. Fabrizio, Shalmali Bane, M. Reinhart, Tim Peoples, Siraj Ali, E. Sokol, G. Frampton, A. Schrock, R. Anhorn, P. Reddy (2019)
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.The oncologist
Boukje Dijk, G. Gatta, R. Capocaccia, D. Pierannunzio, P. Strojan, L. Licitra (2012)
Rare cancers of the head and neck area in Europe.European journal of cancer, 48 6
Tyler Harwood, A. Oliver, S. King, Mahmood Shahlapour, Wishwdeep Dhillon (2020)
Long-Term Durable Response After Treatment of Metastatic Salivary Duct Carcinoma With Pembrolizumab.JCO oncology practice
Steven Gameiro, F. Ghasemi, J. Barrett, J. Koropatnick, A. Nichols, J. Mymryk, S. Vareki (2018)
Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapyOncoimmunology, 7
Mario Sánchez-Canteli, R. Granda-Díaz, N. Rio-Ibisate, E. Allonca, Fernando López-Álvarez, J. Agorreta, I. Garmendia, L. Montuenga, J. García-Pedrero, J. Rodrigo (2020)
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomasCancer Immunology, Immunotherapy, 69
Anjelica Hodgson, E. Slodkowska, A. Jungbluth, Stanley Liu, D. Vesprini, D. Enepekides, K. Higgins, N. Katabi, Bin Xu, M. Downes (2018)
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell CarcinomaThe American Journal of Surgical Pathology, 42
R. Uppaluri, Katie Campbell, A. Egloff, P. Zolkind, Zachary Skidmore, B. Nussenbaum, R. Paniello, Jason Rich, R. Jackson, P. Pipkorn, L. Michel, J. Ley, P. Oppelt, G. Dunn, Erica Barnell, N. Spies, Tianxiang Lin, Tiantian Li, D. Mulder, Y. Hanna, I. Cirlan, Trevor Pugh, Tenny Mudianto, R. Riley, Liye Zhou, V. Jo, M. Stachler, G. Hanna, J. Kass, R. Haddad, J. Schoenfeld, E. Gjini, Ana Lako, W. Thorstad, H. Gay, M. Daly, S. Rodig, I. Hagemann, D. Kallogjeri, J. Piccirillo, R. Chernock, M. Griffith, O. Griffith, D. Adkins (2020)
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II TrialClinical Cancer Research, 26
P. Balermpas, F. Rödel, M. Krause, A. Linge, F. Lohaus, M. Baumann, I. Tinhofer, V. Budach, A. Sak, M. Stuschke, E. Gkika, A. Grosu, A. Abdollahi, J. Debus, S. Stangl, U. Ganswindt, C. Belka, S. Pigorsch, G. Multhoff, S. Combs, S. Welz, D. Zips, S. Lim, C. Rödel, E. Fokas (2017)
The PD‐1/PD‐L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG)International Journal of Cancer, 141
A. Almangush, Lauri Jouhi, T. Atula, C. Haglund, A. Mäkitie, J. Hagström, I. Leivo (2022)
Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working GroupBritish Journal of Cancer, 126
M. Gooden, De Bock, N. Leffers, T. Daemen, H. Nijman (2011)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysisBritish Journal of Cancer, 105
C. Mosconi, J. Arruda, Ana Farias, Gabriella Oliveira, H. Paula, F. Fonseca, R. Mesquita, T. Silva, E. Mendonça, A. Batista (2019)
Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.Oral oncology, 88
T. Seiwert, B. Burtness, R. Mehra, J. Weiss, R. Berger, J. Eder, K. Heath, T. Mcclanahan, J. Lunceford, C. Gause, Jonathan Cheng, L. Chow (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.The Lancet. Oncology, 17 7
Mahmood (2021)
134Int J Radiat Oncol Biol Phys, 109
O. Wood, Jeongmin Woo, G. Seumois, Natalia Savelyeva, Katy McCann, Divya Singh, Terry Jones, Lailah Peel, Michael Breen, Matthew Ward, Eva Martin, Tilman Sanchez-Elsner, Gareth Thomas, P. Vijayanand, Christopher Woelk, Emma King, Christian Ottensmeier (2016)
Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumorsOncotarget, 7
Mélissa Alame, E. Cornillot, V. Cacheux, G. Tosato, M. Four, Laura Oliveira, S. Gofflot, P. Delvenne, Evgenia Turtoi, S. Cabello-Aguilar, M. Nishiyama, A. Turtoi, V. Costes-Martineau, J. Colinge (2019)
The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunitiesTheranostics, 10
B. Cerbelli, Ilaria Girolami, A. Eccher, L. Costarelli, S. Taccogna, R. Scialpi, M. Benevolo, Teresa Lucante, P. Aló, F. Stella, M. Pignataro, G. Fadda, G. Perrone, G. d’Amati, Maurizio Martini (2021)
Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre studyHistopathology, 80
Takahiro Hongo, Hidetaka Yamamoto, Rina Jiromaru, R. Yasumatsu, R. Kuga, Yui Nozaki, K. Hashimoto, M. Matsuo, T. Wakasaki, A. Tamae, K. Taguchi, S. Toh, M. Masuda, Takashi Nakagawa, Y. Oda (2021)
PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinomaModern Pathology, 34
C. Badoual, S. Hans, N. Merillon, Cordélia Ryswick, P. Ravel, N. Benhamouda, E. Levionnois, M. Nizard, A. Si‐Mohamed, Nicolas Besnier, A. Gey, R. Rotem‐Yehudar, H. Péré, T. Tran, C. Guerin, A. Chauvat, E. Dransart, Cécile Alanio, S. Albert, B. Barry, Federico Sandoval, F. Quintin-Colonna, P. Bruneval, W. Fridman, F. Lemoine, S. Oudard, L. Johannes, D. Olive, D. Brasnu, E. Tartour (2013)
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.Cancer research, 73 1
A. Meulenaere, T. Vermassen, S. Aspeslagh, K. Vandecasteele, S. Rottey, L. Ferdinande (2017)
TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?Head and Neck Pathology, 11
M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, Andrew Albright, Jonathan Cheng, S. Kang, S. Ebbinghaus, J. Yearley, V. Shankaran, T. Seiwert, A. Ribas, T. Mcclanahan (2015)
Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumorsJournal for Immunotherapy of Cancer, 3
R. Cristescu, R. Mogg, M. Ayers, Andrew Albright, E. Murphy, J. Yearley, Xinwei Sher, Xiao Liu, Hongchao Lu, M. Nebozhyn, Chunsheng Zhang, J. Lunceford, A. Joe, Jonathan Cheng, A. Webber, N. Ibrahim, E. Plimack, P. Ott, T. Seiwert, A. Ribas, T. Mcclanahan, J. Tomassini, A. Loboda, D. Kaufman (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapyScience, 362
(2017)
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non–small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors, 24
J. Vos, J. Elbers, O. Krijgsman, J. Traets, X. Qiao, A. Leun, Yoni Lubeck, I. Seignette, L. Smit, S. Willems, M. Brekel, R. Dirven, M. Karakullukcu, L. Karssemakers, W. Klop, P. Lohuis, W. Schreuder, L. Smeele, L. Velden, I. Tan, Suzanne Onderwater, B. Jasperse, W. Vogel, A. Al-Mamgani, A. Keijser, V. Noort, A. Broeks, E. Hooijberg, D. Peeper, T. Schumacher, C. Blank, J. Boer, J. Haanen, C. Zuur (2021)
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinomaNature Communications, 12
M. Olmos, J. Glajzer, Tjark-Ole Büntemeyer, G. Frohwitter, J. Ries, M. Eckstein, M. Hecht, R. Lutz, M. Kesting, Manuel Weber (2021)
Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological ResponseFrontiers in Oncology, 11
Simona Crosta, R. Boldorini, F. Bono, Virginia Brambilla, E. Dainese, N. Fusco, A. Gianatti, V. L’Imperio, P. Morbini, F. Pagni (2021)
PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different ProtocolsCancers, 13
Tomio Hayashi, K. Yoshikawa, Susumu Suzuki, M. Gosho, R. Ueda, Y. Kazaoka (2021)
Tumor‐infiltrating FoxP3+ T cells are associated with poor prognosis in oral squamous cell carcinomaClinical and Experimental Dental Research, 8
(2021)
A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma, 109
S. Partlová, J. Bouček, K. Kloudová, E. Lukesova, M. Zábrodský, M. Grega, J. Fucikova, I. Truxova, R. Tachezy, R. Spíšek, A. Fialová (2015)
Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinomaOncoimmunology, 4
J. Fayette, C. Even, L. Digue, L. Geoffrois, F. Rolland, D. Cupissol, J. Guigay, C. Tourneau, A. Dillies, S. Zanetta, Laurence Lemoal, C. Borel, A. Guyennon, Sophie Couchon-Thaunat, V. Costes, I. Jallut, J. Delaye, A. Lardy-Cléaud, S. Chabaud (2019)
NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.Journal of Clinical Oncology
L. Bron, C. Jandus, S. Andrejevic‐Blant, D. Speiser, P. Monnier, P. Romero, J. Rivals (2013)
Prognostic value of arginase‐II expression and regulatory T‐cell infiltration in head and neck squamous cell carcinomaInternational Journal of Cancer, 132
Dianshui Sun, Miao-qing Zhao, M. Xia, Li Li, Yuhao Jiang (2012)
The correlation between tumor-infiltrating Foxp3+ regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancersMedical Oncology, 29
Y-P Chen, Y. Wang, J. Lv, Y-Q Li, M. Chua, Q. Le, N. Lee, A. Colevas, T. Seiwert, D. Hayes, N. Riaz, J. Vermorken, B. O'Sullivan, Q-M He, X. Yang, L. Tang, Yizhi Mao, Y. Sun, N. Liu, J. Ma (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapyAnnals of Oncology, 30
K. Emancipator, Lingkang Huang, D. Aurora-Garg, T. Bal, E. Cohen, K. Harrington, D. Soulières, C. Tourneau, L. Licitra, B. Burtness, R. Swaby (2020)
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancerModern Pathology, 34
P. Balermpas, Y. Michel, Jens Wagenblast, O. Seitz, C. Weiss, F. Rödel, C. Rödel, E. Fokas (2013)
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancerBritish Journal of Cancer, 110
E. Ruiter, M. Ooft, L. Devriese, S. Willems (2017)
The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysisOncoimmunology, 6
B. Ma, Wan-Teck Lim, B. Goh, E. Hui, K. Lo, Adam Pettinger, Nathan Foster, J. Riess, M. Agulnik, Alex Chang, Akhil Chopra, J.A. Kish, Christine Chung, Douglas Adkins, Kevin Cullen, B. Gitlitz, Dean Lim, Ka-Fai To, K. Chan, Y. Lo, Ann King, C. Erlichman, Jun Yin, Brian Costello, Anthony Chan (2018)
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 14
B. Gupta, N. Johnson, Narinder Kumar (2016)
Global Epidemiology of Head and Neck Cancers: A Continuing ChallengeOncology, 91
D. Vital, K. Ikenberg, H. Moch, M. Rössle, G. Huber (2019)
The expression of PD-L1 in salivary gland carcinomasScientific Reports, 9
A. Alberti, L. Lorini, M. Ravanelli, F. Perri, M. Vinches, P. Rondi, C. Romani, P. Bossi (2022)
New Challenges in Evaluating Outcomes after Immunotherapy in Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaVaccines, 10
J. Moy, J. Moskovitz, R. Ferris (2017)
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.European journal of cancer, 76
Zilu Huang, Shan Liu, Guan-nan Wang, S. Zheng, S. Ding, Y. Tao, Chen Chen, Songran Liu, Xin Yang, Hui Chang, Xiao-hui Wang, Yun-Fei Xia (2019)
The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysisCancer Cell International, 19
Ma (2019)
1546Am J Cancer Res, 9
D. Pardoll (2012)
The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 12
E. Cohen, R. Bell, C. Bifulco, B. Burtness, M. Gillison, K. Harrington, Q. Le, Nancy Lee, R. Leidner, Rebecca Lewis, L. Licitra, H. Mehanna, L. Mell, A. Raben, A. Sikora, R. Uppaluri, Fernanda Whitworth, D. Zandberg, R. Ferris (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Journal for Immunotherapy of Cancer, 7
M. Ward, S. Thirdborough, Toby Mellows, C. Riley, S. Harris, K. Suchak, A. Webb, C. Hampton, N. Patel, Connor Randall, H. Cox, S. Jogai, J. Primrose, K. Piper, C. Ottensmeier, E. King, G. Thomas (2013)
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancerBritish Journal of Cancer, 110
A. Egloff, R. Uppaluri (2022)
Preoperative immunotherapy for head and neck cancers: state of artCurrent Opinion in Oncology, 34
V. Sridharan, E. Gjini, X. Liao, N. Chau, R. Haddad, Mariano Severgnini, P. Hammerman, A. El-Naggar, G. Freeman, F. Hodi, S. Rodig, G. Dranoff, J. Schoenfeld (2016)
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating LymphocytesCancer Immunology Research, 4
A. Prat, A. Navarro, L. Paré, N. Reguart, P. Galván, T. Pascual, Alex Martínez, P. Nuciforo, L. Comerma, L. Alós, N. Pardo, S. Cedres, C. Fan, J. Parker, L. Gaba, I. Victoria, N. Viñolas, A. Vivancos, A. Arance, E. Felip (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.Cancer research, 77 13
V. Tchekmedyian, E. Sherman, L. Dunn, Crystal Tran, S. Baxi, N. Katabi, C. Antonescu, I. Ostrovnaya, S. Haque, D. Pfister, A. Ho (2014)
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 18
S. Hendry, R. Salgado, T. Gevaert, P. Russell, T. John, T. John, B. Thapa, M. Christie, K. Vijver, M. Estrada, Paula Gonzalez-Ericsson, M. Sanders, B. Solomon, C. Solinas, G. Eynden, Y. Allory, Y. Allory, M. Preusser, J. Hainfellner, G. Pruneri, A. Vingiani, S. Demaria, F. Symmans, P. Nuciforo, L. Comerma, E. Thompson, S. Lakhani, S. Lakhani, Seong-Rim Kim, S. Schnitt, C. Colpaert, C. Sotiriou, S. Scherer, M. Ignatiadis, S. Badve, R. Pierce, G. Viale, N. Sirtaine, F. Penault-Llorca, Tomohagu Sugie, S. Fineberg, S. Paik, A. Srinivasan, A. Richardson, Yihong Wang, Yihong Wang, E. Chmielik, J. Brock, Douglas Johnson, J. Balko, S. Wienert, V. Bossuyt, S. Michiels, N. Ternès, N. Burchardi, S. Luen, S. Luen, P. Savas, P. Savas, F. Klauschen, P. Watson, B. Nelson, B. Nelson, C. Criscitiello, S. O'toole, D. Larsimont, R. Wind, G. Curigliano, F. André, M. Lacroix-Triki, Mark Vijver, F. Rojo, G. Floris, S. Bedri, J. Sparano, D. Rimm, T. Nielsen, Z. Kos, S. Hewitt, Baljit Singh, G. Farshid, S. Loibl, K. Allison, N. Tung, S. Adams, K. Willard-Gallo, H. Horlings, L. Gandhi, L. Gandhi, Andre Moreira, F. Hirsch, M. Dieci, M. Urbanowicz, I. Brčić, Konstanty Korski, F. Gaire, H. Koeppen, A. Lo, A. Lo, J. Giltnane, M. Rebelatto, K. Steele, J. Zha, K. Emancipator, J. Juco, C. Denkert, J. Reis-Filho, S. Loi, S. Fox (2017)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and MesotheAdvances in anatomic pathology, 24 6
S. Cavalieri, L. Rivoltini, C. Bergamini, L. Locati, L. Licitra, P. Bossi (2018)
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.Cancer treatment reviews, 65
Immunotherapy has shown promising results in the treatment of recurrent and metastatic head and neck cancers. Antiprogrammed cell death (PD)-1 therapies have been recently approved in this setting and they are currently tested also in the treatment of locally advanced diseases and in the neoadjuvant setting. However, the clinical benefits of these treatments have been quite variable, hence the need to select those patients who may obtain the maximal efficacy through the identification of predictive biomarkers. Currently, PD-L1 immunohistochemical expression by tumor and immune cells is the most widely used predictive biomarker for immunotherapy in head and neck squamous cell carcinoma. Nevertheless, patients with PD-L1− tumors may still respond to treatments, thereby emphasizing the need for the identification of other predictive biomarkers. In this review, we summarize the current data on histologic and molecular parameters that can be used to select patients with head and neck cancers for immunotherapy, with a focus on squamous cell carcinoma and salivary gland carcinomas.
Advances in Anatomic Pathology – Wolters Kluwer Health
Published: May 29, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.